

Production and characterization of monoclonal antibodies to *Ebola* glycoproteins

Humberto Hernandez¹, V. Borisevich¹, C. Marceau², A. Marzi², H. Feldmann² and B. Rockx¹

¹University of Texas Medical Branch, USA

²National Institutes Health, MT

Ebolavirus hemorrhagic fever is a severe, often-fatal disease in humans and nonhuman primates, with a case fatality rate of up to 90%. There is currently no vaccine or therapeutic against *Ebolavirus* approved for use in humans. There are five identified species of *Ebolavirus* that include *Bundibugyo*, *Ivory Coast*, *Reston*, *Sudan* and *Zaire* and limited cross-protection is observed between these 5 *Ebolavirus* species. One of the key steps in any virus infection occurs when a virus binds to and enters a cell. The *Ebolavirus* glycoprotein mediates viral attachment and entry into host cells. Based on sequence homology between virus strains, we hypothesize that conserved epitopes are present on the *Ebolavirus* glycoprotein of all known species that can be targeted by monoclonal antibodies. We tested this hypothesis by generating monoclonal antibody producing hybridomas from splenocytes of Balb/c mice vaccinated against *Zaire Ebolavirus* glycoproteins and boosted with *Sudan Ebolavirus* GP. ELISA was used to identify monoclonal antibodies that reacted with the GP of all known *Ebolavirus* species. In an effort to map these conserved epitopes, we performed Western blots to determine whether these antibodies recognized conformational or linear epitopes, and used phage display libraries and sequence analysis to map the epitopes onto the structure of the *Ebolavirus* GP. The monoclonal antibodies produced in this study can be used to further our understanding of mechanisms of filovirus cross-reactivity and develop broad-reactive diagnostics for ebolaviruses.

Biography

Humberto Hernandez completed B.S. in Biology at Lamar University. He is currently part of the Post-Baccalaureate Research Education Program (PREP) at the University of Texas Medical Branch (UTMB). Humberto Hernandez has won several awards including Burroughs Wellcome Fund Travel Award for the ASM National Meeting, travel scholarship, best poster, and presentation award at SACNAS National Conference, and travel award winner for predoctoral poster presentation at the Institute for Human Infections and Immunity (IHII)/ James W. McLaughlin Colloquium at UTMB. He will start his Ph.D. at University of North Texas Health Science Center in Fort Worth, TX in August.

huheman@UTMB.EDU